What Demographic and Clinical Factors Are Associated with In-hospital Mortality in Patients with Necrotizing Fasciitis?


Journal

Clinical orthopaedics and related research
ISSN: 1528-1132
Titre abrégé: Clin Orthop Relat Res
Pays: United States
ID NLM: 0075674

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 14 3 2020
medline: 12 5 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

Necrotizing fasciitis is a rare infection with rapid deterioration and a high mortality rate. Factors associated with in-hospital mortality have not been thoroughly evaluated. Although predictive models identifying the diagnosis of necrotizing fasciitis have been described (such as the Laboratory Risk Indicator for Necrotizing Fasciitis [LRINEC]), their use in predicting mortality is limited. (1) What demographic factors are associated with in-hospital mortality in patients with necrotizing fasciitis? (2) What clinical factors are associated with in-hospital mortality? (3) What laboratory values are associated with in-hospital mortality? (4) Is the LRINEC score useful in predicting mortality? We retrospectively studied all patients with necrotizing fasciitis at our tertiary care institution during a 10-year period. In all, 134 patients were identified; after filtering out patients with missing data (seven) and those without histologically confirmed necrotizing fasciitis (12), 115 patients remained. These patients were treated with early-initiation antibiotic therapy and aggressive surgical intervention once the diagnosis was suspected. Demographic data, clinical features, laboratory results, and treatment variables were identified. The median age was 56 years and 42% of patients were female. Of the 115 patients analyzed, 15% (17) died in the hospital. Univariate and receiver operating characteristic analyses were performed due to the low number of mortality events seen in this cohort. The demographic factors associated with in-hospital mortality were older age (median: 64 years for nonsurvivors [interquartile range (IQR) 57-79] versus 55 years for survivors [IQR 45-63]; p = 0.002), coronary artery disease (odds ratio 4.56 [95% confidence interval (CI) 1.51 to 14]; p = 0.008), chronic kidney disease (OR 4.92 [95% CI 1.62 to 15]; p = 0.006), and transfer from an outside hospital (OR 3.47 [95% CI 1.19 to 10]; p = 0.02). The presenting clinical characteristics associated with in-hospital mortality were positive initial blood culture results (OR 4.76 [95% CI 1.59 to 15]; p = 0.01), lactic acidosis (OR 4.33 [95% CI 1.42 to 16]; p = 0.02), and multiple organ dysfunction syndrome (OR 6.37 [95% CI 2.05 to 20]; p = 0.002). Laboratory values at initial presentation that were associated with in-hospital mortality were platelet count (difference of medians -136 [95% CI -203 to -70]; p < 0.001), serum pH (difference of medians -0.13 [95% CI -0.21 to -0.03]; p = 0.02), serum lactate (difference of medians 0.90 [95% CI 0.40 to 4.80]; p < 0.001), serum creatinine (difference of medians 1.93 [95% CI 0.65 to 3.44]; p < 0.001), partial thromboplastin time (difference of medians 8.30 [95% CI 1.85 to 13]; p = 0.03), and international normalized ratio (difference of medians 0.1 [95% CI 0.0 to 0.5]; p = 0.004). The LRINEC score was a poor predictor of mortality with an area under the receiver operating characteristics curve of 0.56 [95% CI 0.45-0.67]. Factors aiding clinical recognition of necrotizing fasciitis are not consistently helpful in predicting mortality of this infection. Identifying patients with potentially compromised organ function should lead to aggressive and expedited measures for diagnosis and treatment. Future multicenter studies with larger populations and a standardized algorithm of treatment triggered by high clinical suspicion can be used to validate these findings to better help prognosticate this potentially fatal diagnosis.Level of Evidence Level III, therapeutic study.

Sections du résumé

BACKGROUND
Necrotizing fasciitis is a rare infection with rapid deterioration and a high mortality rate. Factors associated with in-hospital mortality have not been thoroughly evaluated. Although predictive models identifying the diagnosis of necrotizing fasciitis have been described (such as the Laboratory Risk Indicator for Necrotizing Fasciitis [LRINEC]), their use in predicting mortality is limited.
QUESTIONS/PURPOSES
(1) What demographic factors are associated with in-hospital mortality in patients with necrotizing fasciitis? (2) What clinical factors are associated with in-hospital mortality? (3) What laboratory values are associated with in-hospital mortality? (4) Is the LRINEC score useful in predicting mortality?
METHODS
We retrospectively studied all patients with necrotizing fasciitis at our tertiary care institution during a 10-year period. In all, 134 patients were identified; after filtering out patients with missing data (seven) and those without histologically confirmed necrotizing fasciitis (12), 115 patients remained. These patients were treated with early-initiation antibiotic therapy and aggressive surgical intervention once the diagnosis was suspected. Demographic data, clinical features, laboratory results, and treatment variables were identified. The median age was 56 years and 42% of patients were female. Of the 115 patients analyzed, 15% (17) died in the hospital. Univariate and receiver operating characteristic analyses were performed due to the low number of mortality events seen in this cohort.
RESULTS
The demographic factors associated with in-hospital mortality were older age (median: 64 years for nonsurvivors [interquartile range (IQR) 57-79] versus 55 years for survivors [IQR 45-63]; p = 0.002), coronary artery disease (odds ratio 4.56 [95% confidence interval (CI) 1.51 to 14]; p = 0.008), chronic kidney disease (OR 4.92 [95% CI 1.62 to 15]; p = 0.006), and transfer from an outside hospital (OR 3.47 [95% CI 1.19 to 10]; p = 0.02). The presenting clinical characteristics associated with in-hospital mortality were positive initial blood culture results (OR 4.76 [95% CI 1.59 to 15]; p = 0.01), lactic acidosis (OR 4.33 [95% CI 1.42 to 16]; p = 0.02), and multiple organ dysfunction syndrome (OR 6.37 [95% CI 2.05 to 20]; p = 0.002). Laboratory values at initial presentation that were associated with in-hospital mortality were platelet count (difference of medians -136 [95% CI -203 to -70]; p < 0.001), serum pH (difference of medians -0.13 [95% CI -0.21 to -0.03]; p = 0.02), serum lactate (difference of medians 0.90 [95% CI 0.40 to 4.80]; p < 0.001), serum creatinine (difference of medians 1.93 [95% CI 0.65 to 3.44]; p < 0.001), partial thromboplastin time (difference of medians 8.30 [95% CI 1.85 to 13]; p = 0.03), and international normalized ratio (difference of medians 0.1 [95% CI 0.0 to 0.5]; p = 0.004). The LRINEC score was a poor predictor of mortality with an area under the receiver operating characteristics curve of 0.56 [95% CI 0.45-0.67].
CONCLUSIONS
Factors aiding clinical recognition of necrotizing fasciitis are not consistently helpful in predicting mortality of this infection. Identifying patients with potentially compromised organ function should lead to aggressive and expedited measures for diagnosis and treatment. Future multicenter studies with larger populations and a standardized algorithm of treatment triggered by high clinical suspicion can be used to validate these findings to better help prognosticate this potentially fatal diagnosis.Level of Evidence Level III, therapeutic study.

Identifiants

pubmed: 32168071
doi: 10.1097/CORR.0000000000001187
pmc: PMC7371088
pii: 00003086-202008000-00015
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1770-1779

Références

Crit Care Med. 1995 Oct;23(10):1638-52
pubmed: 7587228
J Emerg Trauma Shock. 2019 Apr-Jun;12(2):108-116
pubmed: 31198277
Anaesth Intensive Care. 2008 Jan;36(1):51-9
pubmed: 18326132
Scand J Trauma Resusc Emerg Med. 2017 Mar 7;25(1):28
pubmed: 28270166
J Trauma. 2011 Aug;71(2):467-73; discussion 473
pubmed: 21825948
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Infect Dis Clin North Am. 2001 Sep;15(3):775-96
pubmed: 11570141
Plast Reconstr Surg. 2007 May;119(6):1803-1807
pubmed: 17440360
Surgery. 2011 Sep;150(3):363-70
pubmed: 21783216
Arch Surg. 2005 Feb;140(2):151-7; discussion 158
pubmed: 15723996
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Orthop Relat Res. 2010 Aug;468(8):2230-7
pubmed: 20232179
Sci Rep. 2017 Feb 08;7:42179
pubmed: 28176831
Clin Infect Dis. 2007 Aug 15;45(4):450-8
pubmed: 17638193
Clin Infect Dis. 2007 Mar 1;44(5):705-10
pubmed: 17278065
Ann Surg. 2019 Jan;269(1):58-65
pubmed: 29672405
Br J Dermatol. 2017 Dec;177(6):1575-1582
pubmed: 28452064
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Crit Care Med. 2004 Jul;32(7):1535-41
pubmed: 15241098
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
Epidemiol Infect. 2016 Apr;144(6):1338-44
pubmed: 26548496
Am J Respir Crit Care Med. 2016 Feb 1;193(3):281-7
pubmed: 26398704
Am J Kidney Dis. 2015 Nov;66(5):884-930
pubmed: 26498416
Clin Orthop Relat Res. 2006 Jun;447:179-86
pubmed: 16672902
World J Emerg Surg. 2016 Aug 08;11:40
pubmed: 27508002
Front Surg. 2014 Sep 29;1:36
pubmed: 25593960
Crit Care Med. 2008 Jan;36(1):296-327
pubmed: 18158437
Kidney Int. 2010 Mar;77(6):527-35
pubmed: 20032961
Chest. 2016 Jan;149(1):252-61
pubmed: 26378980
J Bone Joint Surg Am. 2003 Aug;85(8):1454-60
pubmed: 12925624
Anaesth Intensive Care. 2009 Jul;37(4):588-92
pubmed: 19681416
Ann R Coll Surg Engl. 2015 Jan;97(1):46-51
pubmed: 25519266
Arch Surg. 1986 Feb;121(2):233-5
pubmed: 3947221

Auteurs

Jaret Karnuta (J)

J. Karnuta, J. Golubovsky, J. Thomas, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.

Joseph Featherall (J)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Joshua Lawrenz (J)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Jaymeson Gordon (J)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Joshua Golubovsky (J)

J. Karnuta, J. Golubovsky, J. Thomas, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.

Jonah Thomas (J)

J. Karnuta, J. Golubovsky, J. Thomas, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.

Deepak Ramanathan (D)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Claus Simpfendorfer (C)

C. Simpfendorfer, Department of Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, USA.

Lukas M Nystrom (LM)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Maja Babic (M)

M. Babic, Department of Infectious Disease, Cleveland Clinic, Cleveland, OH, USA.

Nathan W Mesko (NW)

J. Featherall, J. Lawrenz, J. Gordon, D. Ramanathan, L. M. Nystrom, N. W. Mesko, Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH